Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Filter results: >>>>

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC38	Sirolimus	1	72	flat	flat	HCC38 rapamycin 0 1 72	8	1.723	Inf	0.531	0.429	0.531	0.01	0.623	0.0538	0.573	Inf	0.631	0.66	0.631	0.01	0.536	0.0998	0.661
BT-20	Sirolimus	1	72	flat	flat	BT20 rapamycin 0 1 72	8	2.100	Inf	0.568	0.431	0.568	0.01	-9.89	1.0	0.568	Inf	0.6	0.601	0.6	0.01	-13.0	1.0	0.6
BT-20	Everolimus	3	72	flat	flat	BT20 everolimus 0 3 72	8	2.422	Inf	0.475	0.456	0.475	0.01	0.602	0.0632	0.543	Inf	0.478	0.534	0.478	0.01	0.561	0.0844	0.534
BT-20	Sirolimus	3	72	flat	flat	BT20 rapamycin 0 3 72	8	2.661	Inf	0.54	0.46	0.54	0.01	NA	NA	0.54	Inf	0.499	0.499	0.499	0.01	NA	NA	0.499
BT-549	Sirolimus	3	72	flat	flat	BT549 rapamycin 0 3 72	8	1.703	Inf	0.455	0.482	0.455	0.01	0.376	0.243	0.518	Inf	0.582	0.626	0.582	0.01	0.436	0.179	0.625
BT-20	Everolimus	2	72	flat	flat	BT20 everolimus 0 2 72	8	1.785	Inf	0.426	0.574	0.426	0.01	NA	NA	0.426	Inf	0.547	0.547	0.547	0.01	NA	NA	0.547
BT-20	Sirolimus	2	72	flat	flat	BT20 rapamycin 0 2 72	8	1.952	Inf	0.421	0.579	0.421	0.01	NA	NA	0.421	Inf	0.513	0.513	0.513	0.01	NA	NA	0.513